Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Cyclically Adjusted Revenue per Share: MXN267.10 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ROVIN Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
81 GF Score
Price MXN1,168.82
GF Value MXN1,103.32
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share?

Laboratorios Farmaceuticos Rovi MEX:ROVIN 81 Cyclically Adjusted Revenue per Share is MXN267.10 as of Jun. 2026. GuruFocus rates MEX:ROVIN with a GF Score™ of 81/100 and a GF Value™ of MXN1,103.32. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted revenue per share for the three months ended in Jun. 2026 was MXN75.337. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN267.10 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Laboratorios Farmaceuticos Rovi was 19.90% per year. The lowest was 9.80% per year. And the median was 16.00% per year.

As of today (2026-08-09), Laboratorios Farmaceuticos Rovi's current stock price is MXN1168.82. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN267.10. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio of today is 4.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorios Farmaceuticos Rovi was 11.27. The lowest was 3.39. And the median was 5.52.


Laboratorios Farmaceuticos Rovi  (MEX:ROVIN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1168.82/267.10
=4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorios Farmaceuticos Rovi was 11.27. The lowest was 3.39. And the median was 5.52.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Related Terms


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 138.61 165.91 169.09 237.75 236.03

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 255.81 245.48 236.03 264.73 267.10

MEX:ROVIN vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio falls into.


MEX:ROVIN
81GF Score
Laboratorios Farmaceuticos Rovi SA MEX:ROVIN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=75.337/131.3300*131.3300
=75.337

Current CPI (Jun. 2026) = 131.3300.

Laboratorios Farmaceuticos Rovi Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 27.553 99.737 36.281
201612 32.529 101.842 41.948
201703 27.566 100.896 35.881
201706 29.363 101.848 37.863
201709 28.358 101.524 36.684
201712 34.046 102.975 43.421
201803 34.414 102.122 44.257
201806 32.839 104.165 41.403
201809 32.128 103.818 40.642
201812 34.014 104.193 42.873
201903 32.514 103.488 41.262
201906 37.382 104.612 46.930
201909 36.609 103.905 46.272
201912 41.823 105.015 52.303
202003 47.234 103.469 59.953
202006 42.310 104.254 53.298
202009 52.146 103.521 66.154
202012 51.469 104.456 64.711
202103 57.351 104.857 71.830
202106 69.049 107.102 84.669
202109 75.776 107.669 92.429
202112 78.304 111.298 92.398
202203 83.623 115.153 95.371
202206 69.654 118.044 77.493
202209 75.709 117.221 84.822
202212 95.510 117.650 106.615
202303 74.306 118.948 82.041
202306 62.371 120.278 68.102
202309 75.060 121.343 81.238
202312 156.186 121.300 169.101
202403 53.144 122.762 56.853
202406 68.689 124.409 72.510
202409 100.516 123.121 107.218
202412 185.563 124.753 195.345
202503 66.981 125.531 70.076
202506 67.807 127.251 69.981
202509 88.597 126.840 91.733
202512 90.034 128.400 92.089
202603 62.153 129.860 62.857
202606 75.337 131.330 75.337

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN267.10 mean?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a Cyclically Adjusted Revenue per Share of MXN267.10 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share too high?
Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Revenue per Share is MXN267.10. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share of MXN267.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Revenue per Share is MXN267.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a current Cyclically Adjusted Revenue per Share of MXN267.10. The stock's GF Value™ is MXN1,103.32, compared to a current price of MXN1,168.82 — trading 5.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN267.10. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (MEX:ROVIN), the current Cyclically Adjusted Revenue per Share is MXN267.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of MXN1,168.82 is trading 5.9% above its estimated GF Value™ of MXN1,103.32.

Key valuation signals for MEX:ROVIN:

  • Cyclically Adjusted Revenue per Share: MXN267.10
  • GF Value™: MXN1,103.32 vs. price of MXN1,168.82 (5.9% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the MEX:ROVIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
81GF Score

Get the complete analysis for MEX:ROVIN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,168.82
Price
MXN1,103.32
GF Value